Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia.
The clinical relevance of cellular drug resistance in children with acute lymphoblastic leukaemia (ALL) is unknown. The relation between in-vitro sensitivity to chemotherapeutic drugs at initial diagnosis and long-term clinical outcome was investigated in 44 children with ALL. The short-term MTT assay was used to assess sensitivity to prednisolone, vincristine, colaspase (asparaginase), daunorubicin, and thioguanine (instead of mercaptopurine which is unstable in vitro). For vincristine and colaspase there was no difference in outcome (probability of continuous complete remission) between sensitive and resistant patients. However, the probability of continuous complete remission was significantly lower in patients with resistant cells than in those with sensitive cells for thioguanine (p less than 0.01), daunorubicin (p less than 0.02), and prednisolone (p less than 0.05). For prednisolone there was a significant worsening of the prognosis (p less than 0.05) from the extremely sensitive patients through an intermediate group to the most resistant group. The prognostic significance of cellular drug resistance was independent of white-blood-cell count, age, sex, and hepatosplenomegaly. Leukaemic cells from boys were more resistant to thioguanine than those from girls. Thus, the short-term highly efficient MTT assay can help to predict long-term response to chemotherapy in childhood ALL.
Pieters
R
R
Department of Pediatrics, Free University Hospital, Amsterdam, The Netherlands.
Huismans
D R
DR
Loonen
A H
AH
Hählen
K
K
van der Does-van den Berg
A
A
van Wering
E R
ER
Veerman
A J
AJ
D000970:Antineoplastic Agents / Q000494:pharmacology*; D001215:Asparaginase / Q000494:pharmacology; D016009:Chi-Square Distribution; D002648:Child; D004396:Coloring Agents; D003630:Daunorubicin / Q000494:pharmacology; D004351:Drug Resistance; D004354:Drug Screening Assays, Antitumor; D005260:Female; D006801:Humans; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000401:mortality; D011239:Prednisolone / Q000494:pharmacology; D011379:Prognosis; D012074:Remission Induction; D013778:Tetrazolium Salts; D013844:Thiazoles; D013866:Thioguanine / Q000494:pharmacology; D014407:Tumor Cells, Cultured / Q000187:drug effects*; D014750:Vincristine / Q000494:pharmacology
D000970:Antineoplastic Agents; D004396:Coloring Agents; D013778:Tetrazolium Salts; D013844:Thiazoles; D014750:Vincristine; D011239:Prednisolone; D001215:Asparaginase; C022616:thiazolyl blue; D013866:Thioguanine; D003630:Daunorubicin